By Lina carolina 
Researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, have unveiled a groundbreaking discovery that could significantly expand the reach of life-saving immunotherapy for bowel cancer patients. Their findings, published today in the esteemed journal Cancer Cell, identify the protein CD74 as a critical predictor of response to immunotherapy, potentially unlocking this powerful treatment for hundreds of individuals previously deemed ineligible. This development marks a pivotal moment in the ongoing battle against bowel cancer, the fourth most common cancer and second leading cause of cancer death in the UK.
The intricate landscape of bowel cancer treatment has long been defined by distinct subtypes, largely categorized by the integrity of DNA repair mechanisms. One subtype, characterized by deficiencies in these repair proteins (termed the deficient subtype), has been revolutionized by cancer immunotherapy. These cutting-edge treatments, designed to empower the patient’s own immune system to target and destroy cancerous cells, have offered new hope and significantly improved outcomes for many. However, their efficacy has been limited, with only approximately half of patients with the deficient subtype experiencing a substantial benefit. More critically, individuals diagnosed with the proficient subtype, which constitutes a staggering 90% of all bowel cancer cases, have largely been excluded from immunotherapy, leaving a vast patient population without access to this potentially transformative therapy.
This new research endeavors to bridge this critical gap. The collaborative team meticulously investigated the underlying reasons for immunotherapy’s variable success and explored avenues to broaden its application. Their comprehensive analysis revealed that the expression levels of CD74, a protein found on the surface of certain cells, serve as an independent indicator of immunotherapy response, irrespective of the tumor’s subtype. This revelation is particularly significant as it suggests a universal marker that could transcend existing classification systems and offer a more personalized approach to treatment selection.
Decoding the Immune Microenvironment: The Key to Immunotherapy Success
At the heart of effective immunotherapy lies the complex interplay between the tumor and the surrounding immune microenvironment. The research team’s initial investigations focused on characterizing the types and abundance of immune cells present within and around different bowel tumors. By examining samples from both deficient and proficient subtypes, and critically, from patients who had responded to immunotherapy versus those who had not, they sought to identify the immunological signatures associated with successful treatment.
Their meticulous examination identified a crucial triad of immune cells essential for a robust response to immunotherapy: cytotoxic T cells, often referred to as "fighter cells," which directly attack cancer cells; Natural Killer (NK) cells, another potent immune effector cell; and macrophages, which act as crucial sentinels, presenting tumor-associated antigens to other immune cells, thereby flagging the presence of a threat. When these three cell populations were present in sufficient numbers and strategically positioned in close proximity to cancer cells, they initiated a potent signaling cascade. This cascade involved T cells releasing signaling molecules known as interferons. These interferons, in turn, triggered a response in macrophages and the tumor cells themselves.
In tumors that responded to immunotherapy within the deficient subtype, this signaling pathway was demonstrably amplified. However, the researchers observed a surprising phenomenon: a subset of patients with the proficient subtype, previously considered poor candidates for immunotherapy, also exhibited comparable levels of this crucial immune signal. This finding provided compelling evidence that their immune systems might already be primed for an effective anti-tumor response, suggesting that the proficient subtype is not a monolithic entity in its immunological readiness.
CD74: A Promising Biomarker for Immunotherapy Responsiveness
The critical question then became: how can clinicians reliably and efficiently ascertain if a patient’s immune system is in this optimal state for immunotherapy? The research team turned to cutting-edge technologies, specifically spatial transcriptomics, to identify a straightforward biomarker. This advanced technique allowed them to visualize and analyze gene expression within the intricate cellular architecture of the tumor.
Their spatial transcriptomic analysis revealed that stimulated T cells were inducing nearby macrophages and tumor cells to produce CD74. Furthermore, tumors that were successfully responding to immunotherapy consistently displayed higher levels of CD74 expression. This observation sparked the hypothesis that CD74 could serve as a valuable clinical indicator for predicting immunotherapy outcomes.
To rigorously test this hypothesis, the researchers embarked on a crucial validation phase. They analyzed samples from several international clinical trials that had investigated immunotherapy in cohorts of patients with the proficient subtype of bowel cancer. The results were striking: individuals who exhibited a positive response to immunotherapy demonstrated significantly higher levels of CD74 compared to those who did not respond. This finding strongly suggests that CD74 measurement can predict immunotherapy responsiveness, independently of the tumor’s subtype.
Implications for Clinical Practice and Patient Access
The implications of these findings are profound and far-reaching. Primarily, the ability to measure CD74 levels could dramatically expand the pool of patients eligible for immunotherapy. This includes a significant proportion of individuals with the proficient subtype, who currently face limited therapeutic options beyond conventional chemotherapy and surgery. By identifying these "immunologically ready" proficient subtype patients, clinicians could offer them a chance to benefit from treatments that were previously inaccessible.
Francesca Ciccarelli, Principal Group Leader of the Cancer Systems Biology Laboratory at the Crick and Professor of Cancer Genomics at Queen Mary University of London’s Barts Cancer Institute, articulated the significance of this discovery. "Immunotherapy drugs can be hugely successful for people with bowel cancer, but currently the majority of patients can’t be prescribed these drugs and, even when patients are eligible, we don’t know upfront who will respond," she stated. "Our work suggests that testing for CD74 levels—which signal that the immune system is ‘just right’ to fight the tumour—could widen access to immunotherapy. This could revolutionize treatment for a sizeable fraction of people with the proficient bowel cancer subtype, which is a large number of patients across the UK in real terms. It could also be used to identify people with the deficient subtype who won’t respond, saving them from experiencing side effects unnecessarily."
This dual benefit—identifying responders while also potentially sparing non-responders from the toxicities of ineffective treatments—underscores the clinical utility of CD74 as a predictive biomarker. The prospect of avoiding unnecessary side effects, which can significantly impact a patient’s quality of life, is a critical consideration in oncological care.
Kalum Clayton, a former postdoc at the Crick and joint first author of the study, highlighted the power of interdisciplinary research. "Our work shows how state-of-the-art technologies coupled with computational analysis can address important clinical questions," he remarked. "As an early career research scientist, seeing the potential of our work to provide benefit to patients and their families is greatly rewarding."
The Path Forward: From Bench to Bedside
The research team is not resting on their laurels. They are actively collaborating with Cancer Research Horizons, an organization dedicated to translating scientific discoveries into tangible clinical benefits, to develop the CD74 test into a readily deployable diagnostic tool for routine clinical use. This transition from laboratory findings to clinical application is a crucial step in ensuring that patients can benefit from this research in a timely manner.
Beyond the immediate goal of clinical implementation, the researchers are also delving deeper into the underlying biological mechanisms. They aim to understand precisely why macrophages and tumor cells overexpress CD74 in the context of effective immunotherapy. Further investigation will also explore whether this promising marker is present and predictive in other cancer types, potentially broadening its impact even further across the oncological landscape.
Anna Kinsella, Science Engagement Manager at Cancer Research UK, emphasized the importance of fundamental research in driving progress. "Immunotherapy treatments, such as immune checkpoint inhibitors, use the power of the immune system to fight cancer. Whilst these treatments benefit some people with bowel cancer, they aren’t effective for everyone," she commented. "Although further research is needed, studies like this—diving deep into the biology of tumours—help researchers find ways to predict when immunotherapy is likely to work. In the future, this could help clinicians tailor treatment and allow more people with bowel cancer to benefit from immunotherapy."
She further elaborated on Cancer Research UK’s commitment to discovery research, stating, "Understanding the biology of cancer is vital to unlocking better ways to prevent, detect and treat it, so that people can live longer, better lives free from the fear of cancer. That’s why at Cancer Research UK, discovery research is at the heart of everything we do."
This ambitious research project was a testament to collaborative scientific endeavor, involving contributions from institutions including UCL, the University of Pisa, King’s College London, the Sarah Cannon Research Institute, and the Veneto Institute of Oncology, underscoring the global effort required to tackle complex diseases like cancer.
Broader Impact and Future Directions
The discovery of CD74’s predictive power represents a significant stride towards precision medicine in bowel cancer treatment. Historically, treatment decisions have often relied on broad classifications of tumor subtypes or general patient characteristics. The integration of CD74 testing promises a more nuanced and personalized approach, aligning treatment strategies with an individual’s likely response to immunotherapy. This shift has the potential to not only improve treatment efficacy but also to reduce the burden of ineffective therapies and their associated side effects.
The current landscape of bowel cancer immunotherapy is characterized by a gap between the potential of the treatment and its accessibility. The National Institute for Health and Care Excellence (NICE) in the UK, for instance, provides guidelines for immunotherapy use, typically for specific stages or subtypes of cancer, often with stringent eligibility criteria. The introduction of a robust predictive biomarker like CD74 could lead to revised guidelines and expanded access, potentially impacting thousands of patients annually. For context, if 90% of bowel cancer patients are diagnosed with the proficient subtype, and if even a fraction of these individuals can be identified as potential immunotherapy responders via CD74 testing, the number of eligible patients could rise by tens of thousands across the UK alone.
Furthermore, the research’s success in identifying specific immune cell populations and signaling pathways involved in immunotherapy response opens avenues for combination therapies. Future research could explore ways to enhance the expression of CD74 or to artificially stimulate the necessary immune cell interactions in patients who might not naturally possess the optimal immune microenvironment. This could involve developing novel therapeutic agents or optimizing existing treatment regimens.
The timeline from initial discovery to widespread clinical adoption can be lengthy, often spanning several years. However, the collaborative efforts involving research institutions and commercialization partners like Cancer Research Horizons suggest a proactive approach to accelerating this process. The validation of CD74 in international clinical trials provides a strong foundation for regulatory approval and clinical integration.
In conclusion, the identification of CD74 as a predictive biomarker for immunotherapy response in bowel cancer is a landmark achievement. It signifies a critical step towards more personalized, effective, and accessible cancer care, offering renewed hope to patients and reinforcing the vital role of fundamental scientific inquiry in advancing human health. The ongoing efforts to translate this discovery into a clinical test promise to reshape the future of bowel cancer treatment, bringing the benefits of immunotherapy within reach for a significantly larger patient population.
